Company Overview of REGiMMUNE Corporation
REGiMMUNE Corporation, a biotechnology company, engages in the discovery, development, and commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders. Its products include RGI-2001 for graft versus host disease (GvHD) associated with hematopoietic stem cell transplantation (HSCT) as a proof of concept; and RGI-3010, a immunetolenance inducing liposome encapsulating proinsulin designed to increase the number of regulatory T cells and tolerize the immune system to proinsulin, thereby turning off the self directed immune attack. The company was founded in 2006 and is headquartered in Tokyo, Japan. It has an additional office in Mountain Vie...
Tokyo Industry Trade Center 607 (6th Floor)
Founded in 2006
Key Executives for REGiMMUNE Corporation
Scientific Founder and Executive Chairman
Chief Development Officer and Senior Director
Compensation as of Fiscal Year 2016.
REGiMMUNE Corporation Key Developments
REGiMMUNE Announces Executive Changes
Jul 1 16
REGiMMMUNE announced that its Board of Directors has appointed Kenzo Kosuda as Chief Executive Officer effective July 1, 2016. Yasuyuki Ishii will assume the role of Executive Chairman on July 1, 2016, and will continue to serve as the Chairman of REGiMMUNE’s Board. Kenzo joined REGiMMUNE in 2013. He most recently served as REGiMMUNE’s executive vice president and CFO/COO. REGiMMMUNE also announced that Yasuyuki Ishii, currently President and CEO, will remain on the board and assume the role of Executive Chairman on June 15. He will devote his time to supporting Kenzo and expanding the applications of reVax technology as both inventor and evangelist. Yasuyuki Ishii has served as independent director of REGiMMMUNE since inception, in 2006 and as CEO from 2014.
REGiMMUNE Corporation Appoints Joseph Mccracken to its Board of Directors
Dec 25 15
REGiMMUNE Corporation announced that the Company has appointed Joseph McCracken to its Board of Directors. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives, and serves on the Board of Alkahest Inc., Genkyotex S.A., Savara Pharmaceuticals and Nexvet Biopharma. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries